

Article

Cu(II)-Catalyzed C-N Coupling of (Hetero)aryl Halides and *N*-Nucleophiles Promoted by α -Benzoin Oxime

Chunling Yuan *, Lei Zhang and Yingdai Zhao

Department of Medicinal Chemistry, Pharmacy School, Jinzhou Medical University, Jinzhou 121001, China; hm7835831@163.com (L.Z.); ZYd1216221530@163.com (Y.Z.)

* Correspondence: yuanchunling@jzmu.edu.cn; Tel.: +86-0416-4673440

Received: 29 October 2019; Accepted: 16 November 2019; Published: 18 November 2019



Abstract: We first reported the new application of a translate metal chelating ligand α -benzoin oxime for improving Cu-catalyzed C-N coupling reactions. The system could catalyse coupling reactions of (hetero)aryl halides with a wide of nucleophiles (e.g., azoles, piperidine, pyrrolidine and amino acids) in moderate to excellent yields. The protocol allows rapid access to the most common scaffolds found in FDA-approved pharmaceuticals.

Keywords: α -Benzoin oxime; Copper catalyst; (Hetero)aryl halides; *N*-Nucleophiles; C-N Coupling

1. Introduction

N-Arylated compounds are ubiquitous synthons in numerous natural products and functional molecules [1,2]. Particularly, their most important function is as structural fragment for FDA-approved pharmaceuticals (Figure 1), for example, antibacterial agents (Ofloxacin [3] and Pipemidic acid [4]), antidiabetic drug (Repaglinide [5]), nonsteroidal anti-inflammatory drug (Celecoxib [6]), antihypertensive drug (Prazosin [7]), etc. Although C-N bond-formation reactions between (hetero)aryl halides and *N*-nucleophiles are well known, including the S_NAr reactions [8], classical Ullmann-type coupling reactions [9–11], and Buchwald-Hartwig reactions [12–14]. Amongst Pd-catalyzed C-N coupling reaction has been confirmed as a very useful method to build aromatic amines or arylazoles [15–18]. However, considering to the cost and toxicity of both palladium catalyst and auxiliary phosphine ligands, the arylation of *N*-nucleophiles with (hetero)aryl halides to form new C-N bonds still remains a significant opportunity. In recent years, Cu-catalyzed Ullmann-type couplings have attracted more and more attention due to the inexpensive catalyst and low toxicity. Although many commercially available or novel designed ligands have been developed for promoting copper-catalyzed couplings of aryl halides with *N*-nucleophiles, few of them are effective with less inactivated heterocyclic aryl chlorides. Besides, an easy-removal catalyst system is also very important for the environment.




Figure 1. Chemical structures of selected pharmaceuticals containing the *N*-arylated core.

During the past few years, Ma and co-workers have reported that the oxalic diamide ligands are powerful ligands for the copper-catalyzed couplings [19–21]. In the presence of ligands, the reaction temperature and catalyst loading could be significantly decreased while the yields were increased [22–24]. Following these studies, a number of bidentate ligands were reported for the synthesis of *N*-arylated compounds.


On the other hand, α -benzoin oxime (BO) is a common ligand, which is usually applied to inspect and measure copper, molybdenum, and tungsten [25,26], and also as a chelating agent for extracting antimony, vanadium, tungsten [27]. However, the use of BO in improving the Cu-catalyzed Ullmann style reactions is never reported. Herein, it was found that BO could be used in the direct couplings of the (hetero)aryl halides with *N*-nucleophiles. The reaction allowed rapid access to *N*-arylated compounds, the most common scaffolds found in FDA-approved pharmaceuticals. These reactions were occurred at mild temperature (80 °C), with employing (hetero)aryl halides, nucleophiles (e.g., azoles, piperidine, pyrrolidine and amino acids) and inexpensive catalysts, and affording high yields. Importantly, this process was general with respect to both the (hetero)aryl halides and nucleophiles, including the use of secondary amines and amino acids.

2. Results and Discussions


To initiate our studies, 2-bromoanisole was treated with pyrrole in the presence of 0.28 mol CuI in DMF. Regrettably, coupling product **3a** was obtained in 12% yield, along with unreacted starting material (Table 1, entry 1). The use of Cu powder and Cu(OTf)₂ as catalyst in DMF delivered **3a** in low yields (entries 2, 3). Consistently, Cu(II) gluconate and Cu₂(OH)₂CO₃ did not provide the desired product (entries 4, 5), only a trace of **3a** was observed. In the event, 10 mol% Cu(OAc)₂ enabled the coupling of 2-bromoanisole and pyrrole to provide the desired product in 53% yield (entry 6). Attempts to improve the yield through changing the base were successful, with K₃PO₄ proving to be optimal in terms of yield (entries 6–11). Furthermore, with dioxane, toluene, DCE, H₂O as solvents (entries 12–16), the yield was lower than that in DMF. Fortunately, DMSO gave significantly better results, and **3a** was obtained in a much-improved 90% yield. Meanwhile, lowering the temperature to 60 °C decreased the yield and led incomplete conversion (entry 17). A significant amount of coupling product was observed when using BO as ligand, comparing with the corresponding control experiments (entries 12 and 18). The scalability of this protocol was also tested through synthesis of the **3a** on a 4.4 g scale (entry 19). Additionally, the BO-promoted C-N reaction was also carried out under air, **3a** was obtained in 61% yield, indicating that this catalytic system was sensitive with air (entry 20). Finally, we checked other ligands (including *N,N*-, *N,O*-, *O,O*-type bidentate ligands) that were applied in Cu-catalyzed

N-arylation reactions, and discovered that only **L3** and **L4** could furnish **3a** in moderate yields under standard condition. It was reasoned that these reported ligands may be effective when chelating with Cu(I).

Table 1. Identification of reaction condition ^a.




Entry	Cu Sources	Base	Solvent	Yield (%) ^b
1	CuI	K ₂ CO ₃	DMF	12
2	Cu powder	K ₂ CO ₃	DMF	15
3	Cu(OTf) ₂	K ₂ CO ₃	DMF	22
4	Cu(II) gluconate	K ₂ CO ₃	DMF	Trace
5	Cu ₂ (OH) ₂ CO ₃	K ₂ CO ₃	DMF	Trace
6	Cu(OAc) ₂	K ₂ CO ₃	DMF	53
7	Cu(OAc) ₂	Cs ₂ CO ₃	DMF	60
8	Cu(OAc) ₂	K ₃ PO ₄	DMF	72
9	Cu(OAc) ₂	NaHCO ₃	DMF	0 ^c
10	Cu(OAc) ₂	Et ₃ N	DMF	0 ^c
11	Cu(OAc) ₂	<i>t</i> -BuOK	DMF	Trace
12	Cu(OAc) ₂	K ₃ PO ₄	DMSO	90
13	Cu(OAc) ₂	K ₃ PO ₄	Dioxane	43
14	Cu(OAc) ₂	K ₃ PO ₄	DCE	Trace
15	Cu(OAc) ₂	K ₃ PO ₄	Toluene	0 ^c
16	Cu(OAc) ₂	K ₃ PO ₄	H ₂ O	0 ^c
17	Cu(OAc) ₂	K ₃ PO ₄	DMSO	70 ^d
18	Cu(OAc) ₂	K ₃ PO ₄	DMSO	15 ^e
19	Cu(OAc) ₂	K ₃ PO ₄	DMSO	90 ^f
20	Cu(OAc) ₂	K ₃ PO ₄	DMSO	61 ^g




^a Reaction conditions: 2-Bromoanisole (2.81 mmol), pyrrole (3.37 mmol), Cu source (0.28 mmol), BO (0.28 mmol), solvent (4 mL), base (5.62 mmol), under Ar, at 80 °C, unless otherwise noted for 8 h. ^b Isolated yield with column chromatography. ^c Almost no reaction was observed by TLC. ^d 60 °C. ^e Without BO. ^f The loading of 2-bromoanisole was 28.1 mmol. ^g The reaction was carried out under air. Red bond indicated cleavage bond; blue bond indicated formed bond; and BO was α -benzoin oxime.

With optimized conditions in hand, we set out to evaluate the scope of (hetero)aryl halides that would participate in this transformation (Table 2). The reaction tolerated a diverse array of functional groups on the (hetero)aryl halides, including methoxy (**3a**), aldehyde (**3c**), carboxyl (**3d**), amino (**3e**), ketone (**3f**), ester (**3g**, **3h**), cyano (**3i**). Electronic properties of the (hetero)aryl halides were evaluated by introducing electron-withdrawing and electron-donating groups on the aryl moiety. Although electron-poor (hetero)aryl halides (e.g., **3c**, **3d**, **3i**) underwent coupling faster than electron rich ones (**3a**, **3e**), the desired products were successfully obtained in all cases. Unfortunately, chlorobenzene couldn't provide the product **3b**. By changing which heteroaryl chlorides were employed, couplings were smoothly proceeded, although the yield was decreased. A more sterically encumbered 2-methylimidazole also reacted without incidents (**3l**, **3n**).

Table 2. C-N Coupling reactions of substituted aryl compounds with pyrrole or azoles ^{a,b}.

^a Reactions conducted on (hetero)aryl halides (2.81 mmol), pyrrole or azoles (3.37 mmol), Cu(OAc)₂ (0.28 mmol), BO (0.28 mmol), K₃PO₄ (5.62 mmol), DMSO (4 mL) under Ar at 80 °C for 8–10 h. ^b Isolated yield with column chromatography.


In order to explore the feasibility of this approach, cyclic secondary amines (piperidine and pyrrolidine), acyclic secondary amine (diethylamine), aliphatic primary amine (ethanolamine) were examined to achieve the desired coupling (Table 3). First, the reactions were carried out by using 2-chloropyridine as starting material. To our delight, the corresponding coupling product **4a** and **4b** were obtained in 87% and 88% yield, respectively. We also attempted the coupling of 4-chloropyridine to form **4c** and **4d**. In both cases, the products were obtained in good yields. Both electron-rich (**4g**) and electron-poor (**4i**) aryl bromides participated equally well in the reaction. The reaction was effective in the presence of unprotected polar functional groups such as alcohol. It was encouraged that the ethanolamine substitute could provide **4l** in 90% yield; the lower yield was due to incomplete conversion of the starting material.

Table 3. C-N Coupling reactions of substituted aryl compounds with amines ^{a,b}.

^a Reactions conducted on (hetero)aryl halides (2.81 mmol), amines (3.37 mmol), Cu(OAc)₂ (0.28 mmol), BO (0.28 mmol), K₃PO₄ (5.62 mmol), DMSO (4 mL) under Ar at 80 °C for 8 h. ^b Isolated yield with column chromatography.

Although *N*-heterocycle electrophiles were the primary focus of this study, amino acids-based electrophiles were also evaluated (Table 4). Amino acids underwent coupling to afford corresponding products in moderate yields. Although the yields were modest, it was noted that these reactions were conducted under the conditions developed for the 2-bromoanisole with minimal reoptimization. Substrates bearing either electron-withdrawing (**5b**) or electron-donating groups (**5c**) on the (hetero)aryl halides coupled with high yields. Introduction of an ester group into amino acid was also tolerated (**5a**). Finally, we were pleased to find that our method was not limited to 2-chloropyrimidine. Using 2-chloropyrimidine as the substrate led to the formation of **5e**, **5f** in 86%, 87% yield, respectively.

Table 4. C-N Coupling reactions of substituted aryl compounds with amino acids/esters ^{a,b}.



The ligand BO has been reported to be used as a metal chelating agent [28], which is a typical *N,O*-ligand. Thus, it was believed that the Cu-catalyzed couplings could process in a homogeneous manner due to the formation of Cu-benzoinoxime complex. Herein, it was proposed that the possible mechanism for the couplings might run via a prototypical Cu (I)/Cu (III) catalytic cycle. [29] As shown in Figure 2, the catalytic cycle initiated from a Cu complex (**A**). Then, coordinated copper species (**B**) were produced via oxidative addition of an ArX and **A**. Ligand exchange was subsequently occurred between **A** and *N*-heterocycles to form intermediate **C**, which could be converted to **D** in the presence of base. The *N*-arylazole was obtained by final reductive elimination of **D**.




Figure 2. Proposed mechanism for the couplings of (hetero)aryl halides with *N*-containing heterocycles. NH-Het represented *N*-hetero nucleophiles; X was bromine or chloride.

3. Materials and Methods

All of the starting materials, reagents, and solvents are commercially available and used without further purification. Melting points were determined with a X-4 apparatus (Beijing Taike Instrument Co., Ltd., Beijing, China) and were uncorrected. The nuclear magnetic resonance (NMR) spectra were recorded on a Bruker (Bruker Technology Co., Ltd., Karlsruhe, Germany) 400 MHz spectrometer in CDCl_3 or $\text{DMSO-}d_6$ using tetramethylsilane (TMS) as an internal standard. Electrospray ionization mass spectrometry (MS (ESI)) analyses were recorded in an Agilent 1100 Series MSD Trap SL (Santa Clara, CA, USA). The reactions were monitored by thin-layer chromatography (TLC: HG/T2354-92, GF254), and compounds were visualized on TLC with UV light (Gongyi Yuhua Instrument Co., Ltd, Zhengzhou, China).

General Procedure for Catalytic Experiments

To a solution of (hetero)aryl halide (2.81 mmol), *N*-nucleophile (3.37 mmol), BO (0.28 mmol), K_3PO_4 (5.62 mmol) in DMSO (4 mL), were added $\text{Cu}(\text{OAc})_2$ (0.28 mmol). The flask was evacuated and backfilled with argon for three times. The resulting suspension was heated in a 80 °C oil bath with stirring for the indicated time. The reactor was cooled to r.t., the flask was opened to air and the reaction mixture was poured into water (20 mL), extracted with ethyl acetate (20 mL \times 3), and organic layer was washed with water (20 mL \times 2) and once with brine (25 mL), dried over magnesium sulfate and concentrated *in vacuo*. The product was purified by column chromatography on silica gel using petroleum ether and ethyl acetate as eluent.

1-(2-Methoxyphenyl)-1H-pyrrole (3a) [30]: colorless oil (0.43 g, 88%). $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 7.30–7.23 (2H, m), 7.03–6.98 (4H, m), 6.30 (2H, t, $J = 2.2$ Hz), 3.82 (3H, s). MS (ESI) m/z : 174.11 $[\text{M} + \text{H}]^+$, see Supplementary Materials.

1-Phenyl-1H-pyrrole (**3b**) [31]: white solid (0.38 g, 94%). m.p. 60–62 °C. ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 7.43–7.37 (4H, m), 7.25–7.21 (1H, m), 7.08 (2H, t, *J* = 2.2 Hz), 6.34 (2H, t, *J* = 2.2 Hz). MS (ESI) *m/z*: 144.04 [M + H]⁺.

3-(1H-Pyrazol-1-yl)benzaldehyde (**3c**) [32]: off white solid (0.46 g, 95%), m.p. 28–30 °C. ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 10.08 (1H, s), 8.19 (1H, t, *J* = 1.8 Hz), 8.05–8.02 (2H, m), 7.81–7.76 (2H, m), 7.64 (1H, t, *J* = 7.9 Hz), 6.52 (1H, t, *J* = 2.1 Hz). MS (ESI) *m/z*: 173.08 [M + H]⁺.

2-(1H-Pyrazol-1-yl)benzoic acid (**3d**) [33]: white solid (0.51 g, 96%), m.p. 128–129 °C. ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 11.40 (1H, br), 8.05–8.02 (1H, dd, *J* = 7.8 Hz, 1.2 Hz), 7.76–7.74 (2H, m), 7.62–7.58 (1H, m), 7.49–7.40 (2H, m), 6.48 (1H, s). MS (ESI) *m/z*: 189.06 [M + H]⁺.

2-(1H-Pyrazol-1-yl)aniline (**3e**) [34]: brown oil (0.38 g, 85%). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 7.74–7.71 (2H, m), 7.19–7.13 (2H, m), 6.85–6.76 (2H, m), 6.44 (1H, t, *J* = 2.0 Hz), 4.63 (2H, br). MS (ESI) *m/z*: 160.09 [M + H]⁺.

1-(4-(1H-Pyrazol-1-yl)phenyl)ethan-1-one (**3f**) [35]: yellow oil (0.47 g, 90%). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.08–8.06 (2H, m), 8.02 (1H, d, *J* = 2.5 Hz), 7.83–7.81 (2H, m), 7.78 (1H, d, *J* = 1.4 Hz), 6.53 (1H, t, *J* = 2.0 Hz), 2.63 (3H, s). MS (ESI) *m/z*: 187.09 [M + H]⁺.

Ethyl 3-(1H-pyrazol-1-yl)benzoate (**3g**) [36]: yellow liquid (0.55 g, 91%). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.31 (1H, t, *J* = 1.8 Hz), 7.99 (1H, d, *J* = 2.4 Hz), 7.97–7.93 (2H, m), 7.74 (1H, d, *J* = 1.6 Hz), 7.53 (1H, t, *J* = 8.0 Hz), 6.49 (1H, t, *J* = 2.0 Hz), 4.44–4.38 (2H, q, *J* = 14.3 Hz, 7.2 Hz), 1.41 (3H, t, *J* = 7.1 Hz). MS (ESI) *m/z*: 217.10 [M + H]⁺.

Methyl 4-(1H-pyrazol-1-yl)benzoate (**3h**) [37]: white solid (0.53 g, 93%), m.p. 103–105 °C. ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.15–8.12 (2H, m), 8.00 (1H, d, *J* = 2.4 Hz), 7.80–7.77 (2H, m), 7.76 (1H, d, *J* = 1.4 Hz), 6.51 (1H, t, *J* = 2.1 Hz), 3.93 (3H, s). MS (ESI) *m/z*: 203.11 [M + H]⁺.

2-(1H-Pyrazol-1-yl)benzotrile (**3i**) [38]: yellow oil (0.47 g, 98%). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.15 (1H, d, *J* = 2.5 Hz), 7.81–7.79 (3H, m), 7.77 (1H, d, *J* = 1.3 Hz), 7.72–7.68 (1H, m), 6.55 (1H, t, *J* = 2.1 Hz). MS (ESI) *m/z*: 170.07 [M + H]⁺.

2-(1H-Pyrrol-1-yl)pyridine (**3j**) [39]: colorless oil (0.34 g, 84%). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.43–8.42 (1H, m), 7.75–7.71 (1H, m), 7.52 (2H, t, *J* = 2.3 Hz), 7.32 (1H, d, *J* = 8.3 Hz), 7.11–7.08 (1H, m), 6.36 (2H, t, *J* = 2.3 Hz). MS (ESI) *m/z*: 145.04 [M + H]⁺.

2-(1H-Imidazol-1-yl)pyridine (**3k**) [40]: white solid (0.36 g, 88%), m.p. 40–41 °C. ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.50–8.48 (1H, m), 8.35 (1H, s), 7.85–7.80 (1H, m), 7.65 (1H, t, *J* = 1.3 Hz), 7.37–7.35 (1H, m), 7.27–7.23 (1H, m), 7.20 (1H, s). MS (ESI) *m/z*: 146.08 [M + H]⁺.

2-(2-Methyl-1H-imidazol-1-yl)pyridine (**3l**) [41]: colorless oil (0.38 g, 85%). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.56–8.54 (1H, m), 7.86–7.82 (1H, m), 7.32–7.29 (2H, m), 7.28 (1H, d, *J* = 1.5 Hz), 7.02 (1H, d, *J* = 1.5 Hz), 7.02 (1H, d, *J* = 1.4 Hz), 2.59 (3H, s). MS (ESI) *m/z*: 160.09 [M + H]⁺.

2-(1H-Imidazol-1-yl)pyrimidine (**3m**) [42]: white solid (0.34 g, 83%), m.p. 120–122 °C. ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.71 (2H, d, *J* = 4.8 Hz), 8.64 (1H, s), 7.90 (1H, s), 7.21 (1H, t, *J* = 4.8 Hz), 7.18 (1H, s). MS (ESI) *m/z*: 147.06 [M + H]⁺.

2-(2-Methyl-1H-imidazol-1-yl)pyrimidine (**3n**) [43]: white solid (0.36 g, 80%), m.p. 90–92 °C. ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.72 (2H, d, *J* = 4.8 Hz), 7.86 (1H, d, *J* = 1.4 Hz), 7.18 (1H, t, *J* = 4.8 Hz), 6.97 (1H, d, *J* = 1.3 Hz), 2.82 (3H, s). MS (ESI) *m/z*: 161.10 [M + H]⁺.

2-(Piperidin-1-yl)pyridine (**4a**) [44]: colorless oil (0.40 g, 87%). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 8.16–8.15 (1H, m), 7.44–7.39 (1H, m), 6.63 (1H, d, *J* = 8.6 Hz), 6.54–6.51 (1H, m), 3.52 (4H, d, *J* = 4.9 Hz), 1.62 (6H, s). MS (ESI) *m/z*: 163.13 [M + H]⁺.

2-(Pyrrolidin-1-yl)pyridine (**4b**) [45]: colorless oil (0.37 g, 88%). $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 8.16–8.14 (1H, m), 7.44–7.39 (1H, m), 6.51–6.48 (1H, m), 6.35 (1H, d, $J = 8.5$ Hz), 3.46–3.43 (4H, m), 2.02–1.98 (4H, m). MS (ESI) m/z : 149.12 $[\text{M} + \text{H}]^+$.

4-(Piperidin-1-yl)pyridine (**4c**) [46]: colorless oil (0.39 g, 85%). $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 8.22–8.20 (2H, q, $J = 5.1$ Hz, 1.6 Hz), 6.62–6.61 (2H, q, $J = 5.1$ Hz, 1.6 Hz), 3.31 (4H, d, $J = 4.9$ Hz), 1.63 (6H, s). MS (ESI) m/z : 163.13 $[\text{M} + \text{H}]^+$.

4-(Pyrrolidin-1-yl)pyridine (**4d**) [44]: colorless oil (0.36 g, 86%). $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 8.18 (2H, d, $J = 4.9$ Hz), 6.36 (2H, d, $J = 4.9$ Hz), 3.30–3.27 (4H, m), 2.03–1.99 (4H, m). MS (ESI) m/z : 149.09 $[\text{M} + \text{H}]^+$.

2-(Pyrrolidin-1-yl)pyrimidine (**4e**) [47]: colorless oil (0.37 g, 88%). $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 8.32 (2H, d, $J = 4.8$ Hz), 6.45 (1H, t, $J = 4.8$ Hz), 3.59–3.56 (4H, m), 2.02–1.98 (4H, m). MS (ESI) m/z : 150.11 $[\text{M} + \text{H}]^+$.

2-(Piperidin-1-yl)pyrimidine (**4f**) [47]: colorless oil (0.40 g, 87%). $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 8.30 (2H, t, $J = 5.6$ Hz), 6.42 (1H, t, $J = 5.6$ Hz), 3.81–3.78 (4H, m), 1.72–1.59 (6H, m). MS (ESI) m/z : 164.14 $[\text{M} + \text{H}]^+$.

1-(2-Methoxyphenyl)pyrrolidine (**4g**) [48]: colorless oil (0.40 g, 80%). $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 6.90–6.81 (4H, m), 3.83 (3H, s), 3.30–3.27 (4H, m), 1.95–1.91 (4H, m). MS (ESI) m/z : 178.16 $[\text{M} + \text{H}]^+$.

1-(2-Methoxyphenyl)piperidine (**4h**) [49]: colorless oil (0.44 g, 82%). $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 6.99–6.84 (4H, m), 3.86 (3H, s), 2.99–2.97 (4H, m), 1.78–1.54 (6H, m). MS (ESI) m/z : 192.17 $[\text{M} + \text{H}]^+$.

4-(Pyrrolidin-1-yl)benzaldehyde (**4i**) [50]: white solid (0.44 g, 89%), m.p. 83–85 °C. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 9.72 (1H, s), 7.73 (2H, d, $J = 8.8$ Hz), 6.58 (2H, d, $J = 8.8$ Hz), 3.40–3.37 (4H, m), 2.08–2.02 (4H, m). MS (ESI) m/z : 176.13 $[\text{M} + \text{H}]^+$.

4-(Piperidin-1-yl)benzaldehyde (**4j**) [51]: white solid (0.48 g, 90%). m.p. 63–64 °C. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 9.75 (1H, s), 7.75–7.71 (2H, m), 6.91 (2H, d, $J = 8.9$ Hz), 3.41–3.40 (4H, m), 1.68 (6H, s). MS (ESI) m/z : 190.16 $[\text{M} + \text{H}]^+$.

N,N-Diethylaniline (**4k**) [52]: yellow liquid (0.39 g, 92%). $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 7.23–7.18 (2H, m), 6.69–6.61 (3H, m), 3.37–3.32 (4H, q, $J = 14.1$ Hz, 7.0 Hz), 1.15 (6H, t, $J = 7.1$ Hz). MS (ESI) m/z : 150.12 $[\text{M} + \text{H}]^+$.

2-((4-Nitrophenyl)amino)ethan-1-ol (**4l**) [53]: yellow solid (0.46 g, 90%). m.p. 110–111 °C. $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ (ppm): 8.05 (2H, d, $J = 9.2$ Hz), 7.35 (1H, t, $J = 5.0$ Hz), 6.73 (2H, d, $J = 9.2$ Hz), 4.86 (1H, t, $J = 5.4$ Hz), 3.65–3.61 (2H, q, $J = 11.2$ Hz, 5.6 Hz), 3.31–3.27 (2H, q, $J = 11.4$ Hz, 5.7 Hz). MS (ESI) m/z : 183.08 $[\text{M} + \text{H}]^+$.

tert-Butyl phenyl-*D*-valinate (**5a**) [54]: white solid (0.63 g, 90%), m.p. 64–66 °C. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 7.17–7.13 (2H, m), 6.72–6.69 (1H, m), 6.64–6.62 (2H, m), 4.12 (1H, br), 3.75 (1H, d, $J = 5.3$ Hz), 2.15–2.04 (1H, m), 1.42 (9H, s), 1.05–1.01 (6H, m). MS (ESI) m/z : 250.16 $[\text{M} + \text{H}]^+$.

(4-Nitrophenyl)glycine (**5b**) [55]: brown solid (0.51 g, 92%), 224–226 °C. $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ (ppm): 8.02 (2H, d, $J = 9.0$ Hz), 7.44 (1H, t, $J = 5.6$ Hz), 6.66 (2H, d, $J = 9.1$ Hz), 3.98 (2H, d, $J = 6.0$ Hz). MS (ESI) m/z : 197.08 $[\text{M} + \text{H}]^+$.

Phenyl-*D*-phenylalanine (**5c**) [56]: white solid (0.60 g, 88%), m.p. 173–176 °C. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 7.33–7.17 (7H, m), 6.80 (1H, t, $J = 7.3$ Hz), 6.62 (2H, d, $J = 7.8$ Hz), 4.32 (1H, t, $J = 5.8$ Hz), 3.30–3.10 (2H, m). MS (ESI) m/z : 242.11 $[\text{M} + \text{H}]^+$.

Phenyl-*L*-alanine (**5d**) [57]: white solid (0.42 g, 90%), m.p. 133–135 °C. $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ (ppm): 7.06 (2H, t, $J = 7.8$ Hz), 6.56–6.53 (3H, m), 3.95–3.89 (1H, q, $J = 14.0$ Hz, 7.0 Hz), 1.37 (3H, d, $J = 7.0$ Hz). MS (ESI) m/z : 166.07 $[\text{M} + \text{H}]^+$.

Pyrimidin-2-yl-D-valine (5e): white solid (0.47 g, 86%), 113–115 °C. ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 11.24 (1H, br), 8.25 (2H, s), 7.22 (1H, d, *J* = 8.1 Hz), 6.55 (1H, t, *J* = 4.9 Hz), 4.62–4.59 (1H, q, *J* = 13.1 Hz, 5.0 Hz), 2.37–2.29 (1H, m), 1.06 (6H, t, *J* = 7.2 Hz). MS (ESI) *m/z*: 196.16 [M + H]⁺, 218.11 [M + H]⁺. ¹³C-NMR (100 MHz, CDCl₃) δ (ppm): 176.0, 161.2, 110.4, 59.4, 31.0, 18.9, 18.2.

Pyrimidin-2-ylmethionine (5f): white solid (0.56 g, 87%). ¹H-NMR (400 MHz, CDCl₃) δ (ppm): 13.32 (1H, br), 8.29 (2H, br), 7.92 (1H, d, *J* = 6.6 Hz), 6.62 (1H, t, *J* = 4.9 Hz), 4.88–4.84 (1H, q, *J* = 12.2 Hz, 6.1 Hz), 2.70–2.64 (2H, m), 2.37–2.22 (2H, m), 2.11 (3H, s). MS (ESI) *m/z*: 228.13 [M + H]⁺. ¹³C-NMR (100 MHz, CDCl₃) δ (ppm): 175.8, 160.3, 110.3, 53.7, 31.9, 30.0, 15.4.

4. Conclusions

In summary, a highly effective coupling reaction has been developed for the preparation of *N*-aryl compounds. This transformation occurs with good to excellent yields. A variety of substituted (hetero)aryl halides can be used as electrophiles, and azoles, piperidine, pyrrolidine, and amino acids, etc. function as nucleophiles. The key to this discovery was the identification of benzoin oxime ligand that can promote the (hetero)aryl halides to the corresponding *N*-arylation compounds. Efforts to apply our Cu-based system to other catalytic reactions and to expand the scope of the *N*-nucleophiles to other classes of nucleophiles are currently underway in our laboratory.

Supplementary Materials: The following are available online at <http://www.mdpi.com/1420-3049/24/22/4177/s1>. Copies of ¹H NMR and MS for known compounds and copies of ¹³C NMR for new compounds.

Author Contributions: Conceptualization, C.Y.; Methodology, C.Y. and L.Z.; Software, C.Y.; Formal Analysis, Y.Z. and L.Z.; Writing-Original Draft Preparation, C.Y.; Writing-Review and Editing, C.Y. and Y.Z.; Project Administration, C.Y.

Funding: This research was funded by Liaoning Provincial Natural Science Foundation of China, grant number “2019-BS-102”; College Students Innovation Training Program of Liaoning Province, grant number “201910160017” and “The APC was funded by Liaoning Provincial Natural Science Foundation of China”.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Roughley, S.D.; Jordan, A.M. The medicinal chemist’s toolbox: An analysis of reactions used in the pursuit of drug candidates. *J. Med. Chem.* **2011**, *54*, 3451–3479. [[CrossRef](#)] [[PubMed](#)]
2. Enders, D.; Niemeier, O.; Henseler, A. Organocatalysis by *N*-heterocyclic carbenes. *Chem. Rev.* **2007**, *107*, 5606–5655. [[CrossRef](#)] [[PubMed](#)]
3. Olcay, E.; Beytemur, O.; Kalegasioglu, F.; Gulmez, T.; Mutlu, Z.; Olgac, V. Oral toxicity of pefloxacin, norfloxacin, ofloxacin and ciprofloxacin: Comparison of biomechanical and histopathological effects on Achilles tendon in rats. *J. Toxicol. Sci.* **2011**, *36*, 339–345. [[CrossRef](#)] [[PubMed](#)]
4. Iacovino, R.; Rapuano, F.; Caso, J.V.; Russo, A.; Lavorgna, M.; Russo, C.; Isidori, M.; Russo, L.; Malgieri, G.; Isernia, C. β-Cyclodextrin inclusion complex to improve physicochemical properties of pipemidic acid: Characterization and bioactivity evaluation. *Int. J. Mol. Sci.* **2013**, *14*, 13022–13041. [[CrossRef](#)]
5. Owens, D.R. Repaglinide-prandial glucose regulator: A new class of oral antidiabetic drugs. *Diabet. Med.* **1998**, *15*, S28–S36. [[CrossRef](#)]
6. Liu, C.; Liu, L.; Zhu, H.; Sheng, J.; Wu, X.; He, X.; Tian, D.; Liao, J.; Li, P. Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux. *Sci. Rep.* **2018**, *8*, 4108. [[CrossRef](#)]
7. Yu, C.; Zhu, C.; Xu, S.; Cao, X.; Wu, G. Selective MT2 melatonin receptor antagonist blocks melatonin-induced antinociception in rats. *Neurosci. Lett.* **2000**, *282*, 161–164. [[CrossRef](#)]
8. Kwan, E.E.; Zeng, Y.; Besser, H.A.; Jacobsen, E.N. Concerted nucleophilic aromatic substitutions. *Nat. Chem.* **2018**, *10*, 917–923. [[CrossRef](#)]
9. Monnier, F.; Taillefer, M. Catalytic C-C, C-N, and C-O Ullmann-type coupling reactions. *Angew. Chem. Int. Ed.* **2009**, *48*, 6954–6971. [[CrossRef](#)]
10. Ma, D.; Cai, Q. Copper/amino acid catalyzed cross-couplings of aryl and vinyl halides with nucleophiles. *Acc. Chem. Res.* **2008**, *41*, 1450–1460. [[CrossRef](#)]

11. Surry, D.S.; Buchwald, S.L. Diamine ligands in copper-catalyzed reactions. *Chem. Sci.* **2010**, *1*, 13–31. [[CrossRef](#)]
12. Hartwig, J.F. Carbon-heteroatom bond-forming reductive eliminations of amines, ethers, and sulfides. *Acc. Chem. Res.* **1998**, *31*, 852–860. [[CrossRef](#)]
13. Hartwig, J.F. Transition metal catalyzed synthesis of arylamines and aryl ethers from aryl halides and triflates: Scope and mechanism. *Angew. Chem. Int. Ed.* **1998**, *37*, 2046–2067.
14. Wolfe, J.P.; Wagaw, S.; Marcoux, J.F.; Buchwald, S.L. Rational development of practical catalysts for aromatic carbon-nitrogen bond formation. *Acc. Chem. Res.* **1998**, *31*, 805–818. [[CrossRef](#)]
15. Avila-Sorroza, A.; Estudiante-Negrete, F.; Hernandez-Ortega, S.; Toscano, R.A.; Morales-Morales, D. Buchwald-Hartwig C-N cross coupling reactions catalyzed by a pseudo-pincer Pd(II) compound. *Inorg. Chim. Acta.* **2010**, *363*, 1262–1268. [[CrossRef](#)]
16. Guram, A.S.; Rennels, R.A.; Buchwald, S.L. A simple catalytic method for the conversion of aryl bromides to arylamines. *Angew. Chem. Int. Ed.* **1995**, *34*, 1348–1350. [[CrossRef](#)]
17. Louie, J.; Hartwig, J.F. Palladium-catalyzed synthesis of arylamines from aryl halides. Mechanistic studies lead to coupling in the absence of tin reagents. *Tetrahedron Lett.* **2010**, *36*, 3609–3612.
18. Yang, B.H.; Buchwald, S.L. Palladium-catalyzed amination of aryl halides and sulfonates. *J. Organomet. Chem.* **1999**, *576*, 125–146. [[CrossRef](#)]
19. Zhou, W.; Fan, M.; Yin, J.; Jiang, Y.; Ma, D. CuI/oxalic diamide catalyzed coupling reaction of (hetero)aryl chlorides and amines. *J. Am. Chem. Soc.* **2015**, *137*, 11942–11945. [[CrossRef](#)]
20. Fan, M.; Zhou, W.; Jiang, Y.; Ma, D. CuI/oxalamide catalyzed couplings of (hetero)aryl chlorides and phenols for diaryl ether formation. *Angew. Chem. Int. Ed.* **2016**, *55*, 6211–6215. [[CrossRef](#)]
21. Xia, S.; Gan, L.; Wang, K.; Li, Z.; Ma, D. Copper-catalyzed hydroxylation of (hetero)aryl halides under mild conditions. *J. Am. Chem. Soc.* **2016**, *138*, 13493–13496. [[CrossRef](#)]
22. Pawar, G.G.; Wu, H.; De, S.; Ma, D. Copper(I) oxide/*n,n'*-bis[(2-furyl)methyl]oxalamide-catalyzed coupling of (hetero)aryl halides and nitrogen heterocycles at low catalytic loading. *Adv. Synth. Catal.* **2017**, *359*, 1631–1636. [[CrossRef](#)]
23. Gao, J.; Bhunia, S.; Wang, K.; Gan, L.; Xia, S.; Ma, D. Discovery of *N*-(naphthalen-1-yl)-*n'*-alkyl oxalamide ligands enables Cu-catalyzed aryl amination with high turnovers. *Org. Lett.* **2017**, *19*, 2809–2812. [[CrossRef](#)] [[PubMed](#)]
24. Chen, Z.; Jiang, Y.; Zhang, L.; Guo, Y.; Ma, D. Oxalic diamides and *tert*-butoxide: Two types of ligands enabling practical access to alkyl aryl ethers via Cu-catalyzed coupling reaction. *J. Am. Chem. Soc.* **2019**, *141*, 3541–3549. [[CrossRef](#)] [[PubMed](#)]
25. Korob, R.O.; Cohen, I.M.; Agatiello, O.E. Tungsten and molybdenum co-precipitation by α -benzoin oxime for activation analysis of tungsten: Use of molybdenum as tracer. *J. Radioanal. Chem.* **1976**, *34*, 329–333. [[CrossRef](#)]
26. Gao, Z.; Siow, K.S. Adsorptive stripping voltammetric determination of traces of molybdenum in natural water in the presence of α -benzoinoxime. *Mikrochimica Acta.* **1996**, *124*, 211–218. [[CrossRef](#)]
27. Fan, F.; Bai, J.; Fan, F.; Yin, X.; Wang, Y.; Tian, W.; Wu, X.; Qin, Z. Solvent extraction of uranium from aqueous solutions by α -benzoinoxime. *J. Radioanal. Nucl. Ch.* **2014**, *300*, 1039–1043. [[CrossRef](#)]
28. Joshi, S.R.; Habib, S.I. Synthesis, characterization and antimicrobial evaluation of benzoinoxime transition metal complexes. *J. Chem. Pharm. Res.* **2014**, *6*, 1085–1088.
29. Ribas, X.; Güell, I. Cu(I)/Cu(III) catalytic cycle involved in Ullmann-type cross-coupling reactions. *Pure Appl. Chem.* **2014**, *86*, 345–360. [[CrossRef](#)]
30. Reddy, V.P.; Kumar, A.V.; Rao, K.R. New strategy for the synthesis of *N*-aryl pyrroles: Cu-catalyzed C-N cross-coupling reaction of *trans*-4-hydroxy-L-proline with aryl halides. *Tetrahedron Lett.* **2011**, *52*, 777–780. [[CrossRef](#)]
31. Taillefer, M.; Xia, N.; Ouali, A. Efficient iron/copper co-catalyzed arylation of nitrogen nucleophiles. *Angew. Chem. Int. Ed.* **2007**, *46*, 934–936. [[CrossRef](#)]
32. Zhou, Q.; Du, F.; Chen, Y.; Fu, Y.; Sun, W.; Wu, Y.; Chen, G. L-(–)-Quebrachitol as a ligand for selective copper(0)-catalyzed *N*-arylation of nitrogen-containing heterocycles. *J. Org. Chem.* **2018**, *84*, 8160–8167. [[CrossRef](#)] [[PubMed](#)]

33. Young, M.B.; Barrow, J.C.; Glass, K.L.; Lundell, G.F.; Newton, C.L.; Pellicore, J.M.; Rittle, K.E.; Selnick, H.G.; Stauffer, K.J.; Vacca, J.P.; et al. Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors. *J. Med. Chem.* **2004**, *47*, 2995. [[CrossRef](#)] [[PubMed](#)]
34. de La, H.A.; Diaz-Ortiz, A.; Elguero, J.; Martinez, L.J.; Moreno, A.; Sanchez-Migallon, A. Solvent-free preparation of tris-pyrazolyl-1,3,5-triazines. *Tetrahedron* **2001**, *57*, 4397–4403. [[CrossRef](#)]
35. Li, L.; Zhu, L.; Chen, D.; Hu, X.; Wang, R. Use of acylhydrazine- and acylhydrazone-type ligands to promote CuI-catalyzed C-N cross-coupling reactions of aryl bromides with *N*-heterocycles. *Eur. J. Org. Chem.* **2011**, 2692–2696. [[CrossRef](#)]
36. Cristau, H.-J.; Cellier, P.P.; Spindler, J.-F.; Taillefer, M. Mild conditions for copper-catalyzed *N*-arylation of pyrazoles. *Eur. J. Org. Chem.* **2004**, 695–709. [[CrossRef](#)]
37. Taywade, A.; Chavan, S.; Ulhe, A.; Berad, B. Unique CuI-pyridine based ligands catalytic systems for *N*-arylation of indoles and other heterocycles. *Synth. Commun.* **2018**, *48*, 1443–1453. [[CrossRef](#)]
38. Jia, X.F.; Yang, D.P.; Wang, W.H.; Luo, F.; Cheng, J. Chelation-assisted palladium-catalyzed cascade bromination/cyanation reaction of 2-arylpyridine and 1-arylpyrazole C-H bonds. *J. Org. Chem.* **2009**, *74*, 9470–9474. [[CrossRef](#)]
39. Zhang, X.; Shi, J. Unique chemoselective Clauson-Kass reaction of substituted aniline catalyzed by MgI₂ etherate. *Tetrahedron* **2011**, *67*, 898–903. [[CrossRef](#)]
40. Zhu, L.; Guo, P.; Li, G.; Lan, J.; Xie, R.; You, J. Simple copper salt-catalyzed *N*-arylation of nitrogen-containing heterocycles with aryl and heteroaryl halides. *J. Org. Chem.* **2007**, *72*, 8535–8538. [[CrossRef](#)]
41. Liang, L.; Li, Z.; Zhou, X. Pyridine *N*-oxides as ligands in Cu-catalyzed *N*-arylation of imidazoles in water. *Org. Lett.* **2009**, *11*, 3294–3297. [[CrossRef](#)]
42. Chen, W.; Zhang, Y.; Zhu, L.; Lan, J.; Xie, R.; You, J. A concept of supported amino acid ionic liquids and their application in metal scavenging and heterogeneous catalysis. *J. Am. Chem. Soc.* **2007**, *129*, 13879–13886. [[CrossRef](#)] [[PubMed](#)]
43. Tang, B.X.; Guo, S.M.; Zhang, M.B.; Li, J.H. *N*-Arylations of nitrogen-containing heterocycles with aryl and heteroaryl halides using a copper(I) oxide nanoparticle/1,10-phenanthroline catalytic system. *Synthesis* **2008**, 1707–1716. [[CrossRef](#)]
44. Pedersen, E.B.; Carlsen, D. Phosphoramides; VIII. Phosphorus pentoxide/amine mixtures as reagents in a facile synthesis of dialkylaminopyridines. *Synthesis* **1978**, 844–845. [[CrossRef](#)]
45. Prokopcova, H.; Bergman, S.D.; Aelvoet, K.; Smout, V.; Herrebout, W.; Van der Veken, B.; Meerpoel, L.; Maes, B.U.W. C-2 Arylation of piperidines through directed transition-metal-catalyzed sp³ c-h activation. *Chem-Eur. J.* **2010**, *16*, 13063–13067. [[CrossRef](#)]
46. Hatakeyama, T.; Yoshimoto, Y.; Ghorai, S.K.; Nakamura, M. Transition-metal-free electrophilic amination between aryl grignard reagents and *N*-chloroamines. *Org. Lett.* **2010**, *12*, 1516–1519. [[CrossRef](#)]
47. Narayan, S.; Seelhammer, T.; Gawley, R.E. Microwave-assisted solvent-free amination of halo-(pyridine or pyrimidine) without transition metal catalyst. *Tetrahedron Lett.* **2004**, *45*, 757–759. [[CrossRef](#)]
48. Shim, S.C.; Huh, K.T.; Park, W.H. A new and facile synthesis of *N*-substituted pyrrolidines from amines with aqueous succinaldehyde using tetracarbonylhydridoferrate, HFe(CO)₄⁻, as a highly selective reducing agent. *Tetrahedron* **1986**, *42*, 259–263. [[CrossRef](#)]
49. Lund, H.J. Electroanal. Some reactions of electrochemically prepared anions of DMF and DMSO. *Chem.* **2005**, *584*, 174–181.
50. Fattorusso, C.; Campiani, G.; Kukreja, G.; Persico, M.; Butini, S.; Romano, M.P.; Altarelli, M.; Ros, S.; Brindisi, M.; Savini, L.; et al. Design, synthesis, and structure-activity relationship studies of 4-quinolinyl- and 9-acrydinylhydrazones as potent antimalarial agents. *J. Med. Chem.* **2008**, *51*, 1333–1343. [[CrossRef](#)]
51. Abdel-Aziz, H.A.; Abdel-Wahab, B.F.; El-Sharief, M.A.M.S.; Abdulla, M.M. Synthesis and anti-arrhythmic activity of some piperidine-based 1,3-thiazole, 1,3,4-thiadiazole, and 1,3-thiazolo [2,3-c]-1,2,4-triazole derivatives. *Mon. Fuer Chem.* **2009**, *140*, 431–437. [[CrossRef](#)]
52. Nacario, R.; Kotakonda, S.; Fouchard, D.M.D.; Tillekeratne, L.M.V.; Hudson, R.A. Reductive monoalkylation of aromatic and aliphatic nitro compounds and the corresponding amines with nitriles. *Org. Lett.* **2005**, *7*, 471–474. [[CrossRef](#)] [[PubMed](#)]
53. Nicolaou, K.C.; Snyder, S.A.; Longbottom, D.A.; Nalbandian, A.Z.; Huang, X. New uses for the burgess reagent in chemical synthesis: Methods for the facile and stereoselective formation of sulfamidates, glycosylamines, and sulfamides. *Chem-Eur. J.* **2004**, *10*, 5581–5606. [[CrossRef](#)] [[PubMed](#)]

54. King, S.M.; Buchwald, S.L. Development of a method for the *N*-arylation of amino acid esters with aryl triflates. *Org. Lett.* **2016**, *18*, 4128–4131. [[CrossRef](#)] [[PubMed](#)]
55. Azarifar, D.; Bosra, H.G.; Zolfigol, M.-A.; Tajbaksh, M. Microwave-assisted synthesis of *N*-arylglycines: Improvement of sydnone synthesis. *Heterocycles* **2006**, *68*, 175–181. [[CrossRef](#)]
56. Ma, F.; Xie, X.; Ding, L.; Gao, J.; Zhang, Z. Palladium-catalyzed coupling reaction of amino acids (esters) with aryl bromides and chlorides. *Tetrahedron* **2011**, *67*, 9405–9410. [[CrossRef](#)]
57. Xu, H.; Wolf, C. Copper catalyzed coupling of aryl chlorides, bromides and iodides with amines and amides. *Chem. Commun.* **2009**, 1715–1717. [[CrossRef](#)]

Sample Availability: Samples of the compounds are not available from the authors.



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).